Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Lymphoma Myeloma Leuk. 2017 Jun;17(6):340-346. doi: 10.1016/j.clml.2017.05.004. Epub 2017 May 10.

Metabolic Syndrome in Long-Term Survivors of Hematopoietic Stem-Cell Transplantation.

Author information

1
Department of Clinical Biochemistry and Metabolic Medicine, Guy's Hospital, London, UK.
2
Department of Clinical Biochemistry and Metabolic Medicine, Guy's Hospital, London, UK. Electronic address: martin.crook@doctors.org.uk.

Abstract

Since its introduction more than 50 years ago, hematopoietic stem-cell transplantation (HSCT) has transformed from an inescapably fatal procedure to one where cure from malignant and other nonmalignant hematologic diseases is becoming increasingly common. Nevertheless, longevity is not entirely restored. New causes of mortality have emerged; of particular importance is that of increased cardiovascular disease (CVD), related to metabolic syndrome and its components. Controversy exists over whether the metabolic abnormalities induced are a direct effect of HSCT itself or a consequence of other therapies involved. Analysis of the mechanisms that promote the changes in metabolic components will give insight into future HSCT therapy as well as CVD pathogenesis and prevention.

KEYWORDS:

Bone marrow transplantation; Diabetes mellitus; Lipids; Obesity; Statins

PMID:
28622958
DOI:
10.1016/j.clml.2017.05.004
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center